Evidence map›Paper›PMID 29056779›Full record

ArticleSynthetic communications2016

Synthesis of indolo[4,3-

Mohamed S A Elsayed, Matthias Zeller, Mark Cushman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Synthetic communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The Castagnoli-Cushman Reaction.Molecules (Basel, Switzerland) · 2023
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mohamed S A ElsayedDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University and the Purdue Center for Cancer Research, West Lafayette, Indiana 47907, United States.
Matthias ZellerDepartment of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States.
Mark CushmanDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University and the Purdue Center for Cancer Research, West Lafayette, Indiana 47907, United States.

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI John Tesmer · 1985 to 2026
$43.4M
Novel Topoisomerase I InhibitorsU01CA089566 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI CUSHMAN, MARK S · 2001 to 2014
$3.0M
NCI NIH HHS P30 CA023168NCI NIH HHS U01 CA089566
6 · The paper itself

Abstract

A novel indolophenanthridine ring system has been synthesized via the Schiff base-homophthalic anhydride cyclization followed by thionyl chloride-mediated dehydrogenation and intramolecular Friedel-Crafts acylation. This adds to the array of heterocyclic systems that are available through the cycloaddition reaction of imines with cyclic dicarboxylic acid anhydrides. The cytotoxicities of the indolophenanthridines were investigated in human cancer cell cultures, and the results documented significant antitumor activity in a variety of human cancer cell lines. This provides a new heterocyclic scaffold for anticancer drug design.

Indexed as

anticancercytotoxicityhomophthalic anhydrideIndolophenanthridineSchiff base

Identifiers

PMID29056779
PMCPMC5646376

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.